Identification of a Gene Signature That Predicts Dependence upon YAP/TAZ-TEAD
Targeted therapies are effective cancer treatments when accompanied by accurate diagnostic tests that can help identify patients that will respond to those therapies. The YAP/TAZ-TEAD axis is activated and plays a causal role in several cancer types, and TEAD inhibitors are currently in early-phase...
Main Authors: | Kanai, Ryan, Norton, Emily, Stern, Patrick, Hynes, Richard O., Lamar, John M. |
---|---|
Format: | Article |
Published: |
MDPI AG
2024
|
Subjects: | |
Online Access: | https://hdl.handle.net/1721.1/153660 |
Similar Items
-
Identification of a Gene Signature That Predicts Dependence upon YAP/TAZ-TEAD
by: Ryan Kanai, et al.
Published: (2024-02-01) -
The Telluride YAP/TAZ and TEAD Workshop: A Small Meeting with a Big Impact
by: Guy L. Weinberg, et al.
Published: (2023-09-01) -
The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain
by: Stern, Patrick, et al.
Published: (2013) -
Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive <i>YAP/TAZ–TEAD</i> Biosensors
by: Kazem Nouri, et al.
Published: (2019-10-01) -
FLNC Expression Level Influences the Activity of TEAD-YAP/TAZ Signaling
by: Anastasia Knyazeva, et al.
Published: (2020-11-01)